Dana-Farber Cancer Institute’s Lymphoma Program

04/26/2026

Dr. Christine Ryan, Clinical Director of the Mantle Cell Lymphoma Center, gives an overview of the currently enrolling BRAZEN trial for patients who have just been diagnosed with mantle cell lymphoma or have not been treated for it yet.

04/17/2026

Dr. Mark Murakami and his team in the Murakami lab are advancing the future of cancer care by making biological discoveries that advance the development of safer and more effective treatment for patients with lymphoma by analyzing patient samples for clues as to why some patients respond better to treatment than others. This information helps match patients with the treatments that will benefit them the most.

04/11/2026

At Dana-Farber’s specialized Mantle Cell Lymphoma Center, we connect patients with experts who understand mantle cell lymphoma and are dedicated to advancing treatment and research in that area. We are one of a select few centers nationwide dedicated to advancing research efforts to better understand and treat this type of cancer.

Our goal is simple: to give patients more specialized care, more confidence, and more hope.

For more information about our dedication Mantle Cell Lymphoma Center page visit our website here: https://www.dana-farber.org/cancer-care/types/mantle-cell-lymphoma

04/06/2026

Watch our recent webinar, Learning About Follicular Lymphoma, the second installment of Lymph Notes: A Lymphoma Learning Series.

Philippe Armand, MD, PhD, and Reid Merryman, MD, share updates on recent advancements and treatment options for patients with follicular lymphoma. Dr. Armand discusses treatment considerations for newly-diagnosed patients, and Dr. Merryman discusses treatment for relapsed and refractory patients. In addition, learn about a patient’s personal journey with follicular lymphoma, why they chose Dana-Farber, and their experience participating in a clinical trial.

Philippe Armand, MD, PhD, and Reid Merryman, MD, share updates on recent advancements and treatment options for patients with follicular lymphoma. Dr. Armand...

03/30/2026

Hear from Dana-Farber clinicians on treatment options and ongoing clinical trials for patients with newly diagnosed and relapsed/refractory diffuse large B-cell lymphoma. Our recent webinar, Learning about Diffuse Large B-Cell Lymphoma (DLBCL), covers what DLBCL is, current therapies, and ongoing research, along with a patient perspective on navigating treatment and participating in a clinical trial.


Follow along for more updates on our patient facing webinar series, Lymph Notes: A Lymphoma Learning Series.

Jennifer Crombie, MD, and David Qualls, MD, share updates on treatment options for patients with diffuse large B-cell lymphoma (DLBCL). Dr. Crombie discusses...

03/17/2026

Join us for Living Well With Blood Cancer, a free session hosted by Blood Cancer United for patients, families, and caregivers to learn, connect, and build community with discussions led by Drs. Marlise Luskin, Austin Kim, and Camille Edwards of Dana-Farber Cancer Institute.

Saturday, April 11
10:30 a.m. - 3:00 p.m.

Our afternoon will be focused on Clinical Trial 101: presentations from trusted sources on clinical trial participation, what the clinical process looks like, and clinical trial and treatment updates in blood cancer. Additionally, a panel of blood cancer patients will share their experiences navigating a blood cancer diagnosis. Complimentary breakfast and lunch will be provided.

RSVP at https://bcutd.org/Boston - hope to see you there!

03/09/2026

Dana-Farber Cancer Institute’s Lymphoma Program is excited to launch our Facebook account! The Lymphoma Program provides state-of-the-art, compassionate care for patients with lymphoma. We are committed to providing the best and most individualized treatment options available. Our goal is to share information, resources, research, insights and helpful details about lymphoma and our program on this account, which is tailored specifically to patients, caregivers, families and friends. Help share our new account by clicking on share on the bottom right.